EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model

Yi-Hsiu Tsai, Peng-Yu Wu, Yu-Chi Chuang, Chun-Ying Huang, Hiroki Takeda, Hiroshi Hibino, Chen-Chi Wu, Yen-Fu Cheng

Journal of Clinical Investigation · 2026

DOI: 10.1172/jci193812 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Yi-Hsiu Tsai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Brain Science, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Hauptthemen laut MEDLINE: Genetic Therapy, Sulfate Transporters, Hearing Loss. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, National Science and Technology Council, Taipei Veterans General Hospital-National Taiwan University Hospital Joint Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in SLC26A4 are the second most common cause of hereditary hearing loss (HL) in many Asian countries, leading to DFNB4, a condition characterized by progressive HL and inner ear malformations. While gene therapy holds great potential, its postnatal application has remained unexplored because of the lack of suitable animal models and the challenges of prenatal intervention. To our knowledge, this study represents the first preclinical investigation of postnatal gene therapy for DFNB4 using a clinically relevant Slc26a4 -mutant mouse model that closely replicates human auditory phenotypes. Utilizing the synthetic AAV.Anc80L65 vector, we achieved robust SLC26A4 delivery to critical cochlear regions, including the endolymphatic sac and cochlear lateral wall. Comprehensive phenotypic analyses revealed a critical therapeutic window spanning the neonatal and juvenile stages, within which AAV.Anc80L65-mediated SLC26A4 delivery significantly improved hearing, as evidenced by lower auditory brainstem response thresholds. Moreover, the therapy preserved hair cells, reduced endolymphatic sac enlargement, partially restored the endocochlear potential, and mitigated inner ear structural degeneration. These therapeutic effects persisted into adulthood, highlighting the long-term efficacy of postnatal gene therapy. Together, these findings establish a critical therapeutic window for DFNB4 and demonstrate the feasibility of targeting the endolymphatic sac and cochlear lateral wall for effective intervention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapySulfate TransportersHearing LossAnimalsMiceDisease Models, AnimalHumansDependovirusFemaleGene Therapy AgentsCochleaAuditory Acuity

Stichwörter der Autor:innen

Gene therapyGeneticsOtology

Substanzen

Sulfate TransportersSlc26a4 protein, mouse

Autor:innen und Institutionen

  • Institute of Brain Science, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Gene Therapy Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan.
  • Division of Glocal Pharmacology, Department of Pharmacology, Graduate School of Medicine.
  • Department of Otorhinolaryngology, Graduate School of Medicine, and.
  • Global Center for Medical Engineering and Informatics, The University of Osaka, Osaka, Japan.

Förderung

  • National Health Research Institutes
  • National Science and Technology Council
  • Taipei Veterans General Hospital-National Taiwan University Hospital Joint Research Program
  • Taipei Veterans General Hospital
  • Eli Lilly and Company
  • AMED-CREST

Zitieren

APA

Tsai, Y. H., Wu, P. Y., Chuang, Y. C., Huang, C. Y., Takeda, H., Hibino, H., Wu, C. C., & Cheng, Y. F. (2026). Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model. Journal of Clinical Investigation. https://doi.org/10.1172/jci193812

Vancouver

Tsai YH, Wu PY, Chuang YC, Huang CY, Takeda H, Hibino H, et al. Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model. Journal of Clinical Investigation. 2026. doi:10.1172/jci193812

BibTeX
@article{Tsai2026,
  author = {Tsai, Yi-Hsiu and Wu, Peng-Yu and Chuang, Yu-Chi and Huang, Chun-Ying and Takeda, Hiroki and Hibino, Hiroshi and Wu, Chen-Chi and Cheng, Yen-Fu},
  title = {Postnatal Slc26a4 gene therapy improves hearing and structural integrity in a hereditary hearing loss model},
  journal = {Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1172/jci193812}
}
Kostenlos starten →